Needham & Company Positive on Lexicon Pharma (LXRX) Following Sotagliflozin Phase 3 Data; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St set to open lower as Meta Platforms, economic data weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- US dollar briefly falls vs yen after GDP data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Wedbush Raise Lexicon Pharmaceuticals (LXRX) PT to $33 as Primary Endpoint Reached
September 9, 2016 11:57 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $33.00 after sotagliflozin achieves its primary endpoint in first T1D phase III trial.
Moussatos commented, "With inTandem1 for Type 1 diabetes (T1D)... More
Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 3 in T1D Met Primary Endpoint
September 9, 2016 6:59 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in... More
